CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 Relapsed/Refractory Malignancies.
We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19 malignancies. Patients rec...